Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIC phase 3 trial of MST-188 for vaso-occlusive crisis in sickle cell disease
2013-002986-21Phase 3Completed
- Sponsor
- Mast Therapeutics, Inc.
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sickle cell disease (SCD) comparing MST-188 with Placebo (2 arms). Started Apr 2014; status: completed.
02
Drugs
vepoloxamer
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on 2013-002986-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002986-21.